5.3.4 Influenza

Back

5.3.1 HIV infection 5.3.2 Herpes virus infections 5.3.3 Viral hepatitis 5.3.4 Influenza 5.3.5 Respiratory syncytial virus (RSV) 5.3.6 nMABs and other antiviral drugs

Chapter 5: Infections Toggle Parent Pages

Principles of antibacterial treatment Upper respiratory tract infections Lower respiratory tract infections Acute exacerbation of bronchiectasis (non-cystic fibrosis) Urinary tract infections (UTI) Gastro-intestinal tract infections Genital tract infections Skin and soft tissue infections Eye infections Oral and dental infections Lyme disease guidance Meningitis guidance Methicillin Resistant Staphylococcus Aureus (MRSA) guidance COVID-19 treatments for patients who do not require hospitalisation 5.1 Antibacterial drugs 5.2 Antifungal drugs 5.3 Antiviral drugs 5.4 Antiprotozoal drugs 5.5 Anthelmintics

Print this page

First Line

Second Line

Specialist

Hospital Only

Please refer to the information on the prescribing oseltamivir or zanamivir for the treatment and prophylaxis of influenza and including NICE guidance.

NICE TA158: Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (September 2008)

NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza (February 2009)

NICE Guidance for the use of antivirals for seasonal influenza does not apply in an influenza pandemic, other guidelines will be issued.

Oseltamivir

Capsules 30mg, 45mg, 75mg (£7.71 = 10 x 30mg)
Oral suspension^SF 6mg/ml (£10.27 = 65ml)

Notes

Resistance to oseltamivir has arisen more frequently than previously reported in children treated for influenza. This should be borne in mind when treating children in 'at risk' groups, in accordance with NICE guidance.

Zanamivir

Inhalation powder blisters with device 5mg (£16.36 = 20 blister units)
Solution for infusion vials 200mg/20ml (University Hospitals Plymouth NHS Trust only)

Formulary

5.3.4 Influenza

Oseltamivir

Zanamivir